The Integrated Genomics Operation (IGO) Core provides a broad range of services and expertise to Center investigators interested in evaluating gene expression, chromosome structure, and nucleotide sequence on a broad scale. It delivers a comprehensive, rapid, and user-friendly service. IGO enables basic, clinical, and translational research projects across the Center. Through the centralized management of all sequencing activities at MSK, the Core empowers scientists with an array of technological options and the most efficient and cost-effective means of performing high-throughput genomics. Through its production group, the Core supports most functional genomics applications for analysis of DNA and RNA and has the expertise to successfully process challenging samples from all origins (tissue, cell pellets, paraffin curls, blood, serum, etc.). This expertise is particularly important for investigators studying heterogenous tumor types from the MSK tumor bank. If needed, this group can operate in a highly automated environment, from sample reception to sequencing library preparation. The production group is a LEAN operation that minimizes waste and maximizes value at every step. Consequently, turnaround times and prices are competitive with those offered by commercial and other academic entities. The IGO also provides a customized service to investigators wishing to explore new frontiers in applications and technologies. The Informatics group of the Core provides end-to-end software engineering and bioinformatic analysis solutions to the users of its sequencing services. The broad range of services provided by the IGO Core has supported research of 377 investigators in the past year. During the past grant period, the work of the Core has contributed to 882 publications across all programs; 237 of these publications were published in high impact journals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084834
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8
Motzer, Robert J; Escudier, Bernard; Powles, Thomas et al. (2018) Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176-1178
Giancipoli, Romina Grazia; Monti, Serena; Basturk, Olca et al. (2018) Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report. Medicine (Baltimore) 97:e12795
Karimov, Rashad R; Tan, Derek S; Gin, David Y (2018) Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement-intramolecular ketene hetero-Diels-Alder reaction. Tetrahedron 74:3370-3383
Fass, Josh; Sivak, David A; Crooks, Gavin E et al. (2018) Quantifying Configuration-Sampling Error in Langevin Simulations of Complex Molecular Systems. Entropy (Basel) 20:
Mauguen, Audrey; Seshan, Venkatraman E; Ostrovnaya, Irina et al. (2018) Estimating the probability of clonal relatedness of pairs of tumors in cancer patients. Biometrics 74:321-330
Tanner, Edward J; Filippova, Olga T; Gardner, Ginger J et al. (2018) A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol 151:433-437
Arbour, Kathryn C; Kris, Mark G; Riely, Gregory J et al. (2018) Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 124:105-109
Soslow, Robert A; Murali, Rajmohan (2018) A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract. Semin Diagn Pathol 35:95-107
Kao, Yu-Chien; Owosho, Adepitan A; Sung, Yun-Shao et al. (2018) BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42:604-615

Showing the most recent 10 out of 8799 publications